Syndax Pharmaceuticals (SNDX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

SNDX Syndax Pharmaceuticals

Watchlist

17.080
+0.460+2.77%

Trading Dec 4 13:50 ET

1.46BMarket Cap-4692P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersDec 3 16:05 ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireDec 3 16:05 ET
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
PR NewswireNov 27 07:00 ET
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Seeking AlphaNov 25 13:58 ET
Trending Stocks Today | Molecular Templates Surges 43.71% Post-Market
Moomoo NewsNov 21 16:30 ET
Analysts Supportive of Kura/Kirin Deal Despite Major Selloff in Shares
Seeking AlphaNov 21 12:14 ET

Comments

Jaguar8

Nov 17 13:32

J.P. Morgan analyst has maintained their bullish stance on stock, giving a Buy rating on November 13. Goldman Sachs give it price target $31.

$Syndax Pharmaceuticals (SNDX.US)$

Jaguar8

Nov 16 16:41

My watchlist Monday. Why? FDA approval- first of its kind for acute adult and pediatric leukemia

$Syndax Pharmaceuticals (SNDX.US)$

Trytosaveabit

Nov 15 18:07

Repost of FDA approval! Longer PR because to me this seems like a pretty big deal? More so than most approvals! JMO

$Syndax Pharmaceuticals (SNDX.US)$ But im sure/hoping Dr @Jaguar8 will either confirm or dispute! To me seems pretty AWESOME! ((((((. Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
1 HOUR AGO, 5:29 PM EST
VIA PR NEWSWIRE
– Approva...

Jaguar8

Nov 15 16:32

NEWS RECAP

$Syndax Pharmaceuticals (SNDX.US)$
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation